What is behind Novo Nordisk stock's recent drop in value today

Traders Union
All News
Financial News
Novo Nordisk slides 3.93% today

All news

Editors' Picks

Crypto News

Financial News

Market Voices

Billionaires

Companies

Broker News

Regulators News

Dan Blystone

02.06.2026

What is behind Novo Nordisk stock's recent drop in value today — Novo Nordisk slides 3.93% today

Novo Nordisk A/S (NVO) is trading at $42.34, positioned near the low of today’s range and below all major daily moving averages except for the MA-50 at $41.25, which currently sits just below the market price. This configuration indicates ongoing short- and medium-term supply pressure.

NVO price prediction

24H 0.59%

$44.36

48H 0.61%

$44.37

7D 4.92%

$46.27

1M 7.41%

$47.37

3M -28.8%

$31.4

6M -27.51%

$31.97

12M -35.22%

$28.57

Detailed

Current price: $ 44.1 2.10 5.00%

Real-time Data 12:47

Daily range 43.32

44.37

Weekly range 41.91

45.89

Highlights

Novo Nordisk's first quarter 2026 earnings per share of $1.04 beat consensus, driven by consistent cash generation in diabetes and obesity treatments.
The company advanced its DKK 15 billion buyback program, acquiring 17.9 million B shares for DKK 4.71 billion and holding 0.8% as treasury stock.
Shares face persistent supply pressure, trading below key averages with an expected five-session range of $40.94–$44.44 and low near-term rebound probability.

Share buyback and earnings beat contrast with persistent selling

Novo Nordisk continued progress on its ongoing DKK 15 billion share buyback program, launched on May 6, 2026, with approximately 17.9 million B shares repurchased for DKK 4.71 billion as of May 29, 2026. The company held 35,074,480 B shares, or about 0.8% of total share capital, as treasury stock under the EU Safe Harbour rules. First quarter 2026 financial results surpassed consensus, reporting earnings per share of $1.04, with steady equity performance attributed to strong cash generation in diabetes and obesity therapeutics, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, highlights that Novo Nordisk’s price action remains weak despite positive buyback news and fundamental strength. He observes clear short- and medium-term supply pressure, noting sellers firmly in control intraday and a failure for technicals to signal near-term upside. Oversold readings have not spurred a reversal, and the price is stuck below key averages. Kharitonov notes that the buyback and strong earnings have not shifted overall market sentiment. "Exposure here carries elevated risk unless $44.44 is reclaimed, and I see deeper downside likely if $40.94 support breaks," he says.

Viktoras Karapetjanc, expert at Traders Union, sees continued strategic buybacks and outperformance in core therapeutics as evidence of strong underlying fundamentals. He emphasizes that the company's steady cash flow and treasury management demonstrate resilience, despite broader market volatility. Karapetjanc believes Novo Nordisk's structure remains bullish, with fundamentals providing a base for recovery opportunities. "I expect further growth driven by robust operations, so investors should look for renewed momentum if resistance at $44.44 is cleared," he states.

Jainam Mehta, market strategist, notes a divergence between technical momentum and price, with mixed MACD signals but a persistent oversold bias on oscillators. He sees tactical setups emerging if sentiment shifts, especially given the volatility band of $40.94–$44.44. Mehta suggests contrarian entries may develop if strong support holds despite recent selling. "Watch for a potential breakout above $44.44 or aggressive short-covering if oversold conditions persist," he recommends.

Divergent momentum as sellers dominate despite oversold signals

Momentum signals are mixed: MACD points to strong daily upward potential, but the Average Directional Index (ADX) on the daily chart reads neutral, and most oscillators — including the Relative Strength Index (RSI), Commodity Channel Index (CCI), and Stochastic RSI — are tilting oversold. Bull/Bear Power (BBP) shows sellers dominating intraday momentum, reinforcing the oversold signal. The stock is down 3.93% on the day despite a $1.32 upside gap at the open, with intraday volatility at 3.18% and clear pressure after the open. This sharp intraday sell-off does not fully match the persistent oversold and mixed momentum signals, highlighting a divergence between momentum and price action.

Earlier, analysts noted that Novo Nordisk shares remained under downside pressure despite company buybacks and resilient cash flows, with mixed technical momentum weighing on short-term outlook. The latest developments reinforce this view, as fresh financial results and accelerating buybacks have not reversed prevailing selling pressure, highlighting $40.94 as a key support level for traders to monitor for potential further downside.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.